Yago Garitaonaindía, Professor at University of Copenhagen (Københavns Universitet), shared a post on LinkedIn:
“In respectable NSCLC, the question has changed.
Perioperative chemo-immunotherapy is now standard of care. It’s no longer about whether it works — it’s who needs more treatment, and who can safely be spared.
Our new review is out in Nature Reviews Clinical Oncology, where we lay out how to move from uniform intensification toward a response-adaptive, biology-guided perioperative strategy.
Four pillars:
- pCR as a robust surrogate of durable benefit – 5-yr OS >95% in patients achieving pCR (CheckMate 816 & NADIM)
- Baseline biomarkers (PD-L1, genomics) to flag upfront who is unlikely to respond
- Dynamic tools (ctDNA, radiomics, metabolic imaging) to adapt treatment in real time
- Intensify in the biologically high-risk; de-escalate where it’s safe
The bottom line: one-size-fits-all is no longer good enough. The future of perioperative NSCLC is adaptive and biomarker-driven.
Deeply grateful to an outstanding group of co-authors — Heather Wakelee, Martin Reck, Patrick Forde, Tina Cascone and Jonathan Spicer — and to my mentor and senior author, Mariano Provencio, for the trust and guidance throughout.”
Title: Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
Authors: Yago Garitaonaindia, Heather A. Wakelee, Martin Reck, Patrick M. Forde, Tina Cascone, Jonathan D. Spicer, Mariano Provencio
Read the Full Article.
Other articles featuring Yago Garitaonaindía on OncoDaily.
